A Comprehensive Analysis of Risk Factors of Diabetic Nephropathy and Exploring the Treatment Pattern
Aritra Pal *
Aditya Pharmacy College, Surampalem, 533437, Andhra Pradesh, India.
Asish Bhanja
Aditya Pharmacy College, Surampalem, 533437, Andhra Pradesh, India.
Joy Williams
Aditya Pharmacy College, Surampalem, 533437, Andhra Pradesh, India.
Vineesha Geddam
Aditya Pharmacy College, Surampalem, 533437, Andhra Pradesh, India.
Chandana Bendurthi
Aditya Pharmacy College, Surampalem, 533437, Andhra Pradesh, India.
Bipin Sah
Aditya Pharmacy College, Surampalem, 533437, Andhra Pradesh, India.
Bashongdor Marwein
Aditya Pharmacy College, Surampalem, 533437, Andhra Pradesh, India.
Arka Ghosh
Aditya Pharmacy College, Surampalem, 533437, Andhra Pradesh, India.
Anurag Rajkonwar
Aditya Pharmacy College, Surampalem, 533437, Andhra Pradesh, India.
Praveen Sana
Trust Multispeciality Hospital, India.
Ratna Kumari
Aditya Pharmacy College, Surampalem, 533437, Andhra Pradesh, India.
*Author to whom correspondence should be addressed.
Abstract
Aims: The study aims to comprehensively analyze diabetic nephropathy's risk factors and treatment patterns, exploring diverse factors for enhanced prevention and personalized management.
Study Design: Prospective study design.
Place and Duration of Study: The study was conducted for 5 months at Trust Multispeciality Hospital, Kakinada.
Methodology: This retroactive chart analysis of non-critical outpatients folders of Trust Hospital that refers to the mentioned period (11/2022 -04/2023) will use Excel software.
Results: A variety of risk factors promote the development and progression of diabetic nephropathy, including elevated glucose levels, high blood pressure, obesity, the long duration of diabetes, and dyslipidemia. These risk factors are modifiable by hyperglycemic agents, anti-hypertensives, and lipid-lowering agents. Most of the people who are prone to diabetic nephropathy are between 40 and 70 years of age. Males are most affected (80%) compared to females (20%). Oral hypoglycemic agents (97%) and calcium channel blockers (50%) play a major role in reducing the progression of diabetic nephropathy by controlling blood pressure and glucose levels in the subject. Obesity is also a notable risk factor for end-stage renal disease patients.
Keywords: Diabetic nephropathy, end stage renal disease, hyperglycemia, obesity, anti-hypertensive, dyslipidemia